Kidney transplant plus blood-cell treatment to help the graft settle
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and under 65 years old
- You have end-stage kidney disease and are already a new kidney transplant candidate through the standard process
- You must have at least a partial immune match with the donor (HLA match in A, B, or DR)
- You must be able to sign consent and follow birth control rules for at least 1 year after transplant (if able to have children)
- You must not be allergic to rabbit medicines (rabbit ATG) or have a medical reason you can’t safely receive low-dose radiation
- You can’t have certain infections or blood count problems, including HIV, hepatitis B/C, active infections, very low white blood cells, or very low platelets
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
This trial tests a new combination of radiation and antibody treatment for people receiving a liver transplant at Stanford. The goal is to help your new liver last longer by training your immune system to accept it while reducing the need for lifelong anti-rejection drugs.
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Hear when a new Immune Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.